Bone Biologics Corp financial data

Symbol
BBLG, BBLGW on Nasdaq
Location
2 Burlington Woods Drive,, Suite 100,, Burlington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.49K % +55.9%
Debt-to-equity 7.2 % -38.4%
Return On Equity -83 % +33.4%
Return On Assets -77.5 % +30.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.8M shares -27.1%
Common Stock, Shares, Outstanding 1.8M shares -14.4%
Entity Public Float 1.57M USD -62.4%
Common Stock, Value, Issued 1.8K USD -14.4%
Weighted Average Number of Shares Outstanding, Basic 1.8M shares +514%
Weighted Average Number of Shares Outstanding, Diluted 1.8M shares +514%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.91M USD +29.5%
General and Administrative Expense 2.15M USD -8.6%
Operating Income (Loss) -4.06M USD -6.08%
Nonoperating Income (Expense) 111K USD +384%
Net Income (Loss) Attributable to Parent -3.95M USD +4.7%
Earnings Per Share, Basic 12 USD/shares +7.91%
Earnings Per Share, Diluted 12 USD/shares +7.91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.19M USD +6.43%
Assets, Current 6.35M USD +56.2%
Assets 6.35M USD +56.2%
Liabilities, Current 334K USD +22.3%
Liabilities 334K USD +22.3%
Retained Earnings (Accumulated Deficit) -87.4M USD -4.73%
Stockholders' Equity Attributable to Parent 6.02M USD +58.6%
Liabilities and Equity 6.35M USD +56.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -926K USD +28.9%
Net Cash Provided by (Used in) Financing Activities 348K USD -76.9%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.8M shares -14.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -579K USD -388%
Deferred Tax Assets, Valuation Allowance 21.7M USD +6.23%
Deferred Tax Assets, Gross 21.7M USD +6.23%
Deferred Tax Assets, Operating Loss Carryforwards 10.8M USD +12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 93.5M USD +7.07%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%